The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Antigen presentation suppression as a hallmark of immune evasion and poor outcomes in small cell lung cancer.
 
Triparna Sen
Research Funding - Debiopharm Group; Jazz Pharmaceuticals
 
Elisa Gobbini
Employment - AstraZeneca (I)
Research Funding - AstraZeneca (Inst); SERVIER
Travel, Accommodations, Expenses - Bristol Myers Squibb; Johnson & Johnson/Janssen; Takeda
 
Vrinda Jethalia
No Relationships to Disclose
 
Subhamoy Chakraborty
No Relationships to Disclose
 
Ari Vanderwalde
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Consulting or Advisory Role - George Clincal; West Clinic
 
Balazs Halmos
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Novartis; Nuvalent, Inc.; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Forward (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst); Tesaro/GSK (Inst)
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen Oncology; Jazz Pharmaceuticals; Pfizer; Regeneron; Regeneron
Consulting or Advisory Role - Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Gilead Sciences; Grid Therapeutics; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Novocure; Pfizer; PharmaMar; Puma Biotechnology; RAPT Therapeutics; Regeneron; Rgenix; Summit Therapeutics; Systimmune; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Genentech; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Deniz Demircioglu
No Relationships to Disclose
 
Dan Hasson
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences